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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 226 (FGE.226): 
Consideration of genotoxicity data on one α,β-unsaturated aldehyde from 
chemical subgroup 1.1.1(b) of FGE.19 by EFSA1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of one flavouring substance from subgroup 1.1.1(b) 
of FGE.19 in the Flavouring Group Evaluation 226. The Flavour Industry has provided additional genotoxicity 
studies for the substance [FL-no: 16.071] in FGE.226. Based on these new data the Panel concluded that 4,5-
epoxydec-2(trans)-enal did not induce gene mutations in bacterial cells but was positive in an in vitro 
micronucleus assay, so, 4,5-epoxydec-2(trans)-enal is considered an in vitro genotoxic agent. The negative 
results obtained in an in vivo micronucleus assay cannot overrule the positive results of the in vitro micronucleus 
assay with and without S9-mix due to the lack of cytotoxicity in the bone marrow. On this basis, an in vivo 
Comet assay in rodents is recommended in order to verify possible genotoxic effects at the first site of contact 
(e.g., stomach/duodenum cells). 
© European Food Safety Authority, 2012 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Scientific Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission 
on the implications for human health of chemically defined flavouring substances used in or on 
foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The present Flavouring Group Evaluation 226 (FGE.226), corresponding to subgroup 1.1.1(b) of 
FGE.19, concerns one α,β-unsaturated aldehyde which also include an epoxide, 4,5-epoxydec-
2(trans)-enal [FL-no: 16.071]. The α,β-unsaturated aldehyde structure is considered to be a structural 
alert for genotoxicity and the data on genotoxicity previously available did not rule out the concern for 
genotoxicity. 
To evaluate the genotoxic potential of 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] the Panel has 
therefore requested additional genotoxicity data according to the test strategy worked out by the Panel. 
According to the above requirements, the Industry has submitted additional genotoxicity studies for 
4,5-epoxydec-2(trans)-enal. 
Based on these new data the Panel noted that 4,5-epoxydec-2(trans)-enal did not induce gene 
mutations in bacterial cells but was positive in an in vitro micronucleus assay, so, 4,5-epoxydec-
2(trans)-enal is considered an in vitro genotoxic agent. The negative results obtained in an in vivo 
micronucleus assay cannot overrule the positive results of the in vitro micronucleus assay with and 
without S9-mix due to the lack of cytotoxicity in the bone marrow. On this basis, an in vivo Comet 
assay in rodents is recommended in order to verify possible genotoxic effects at the first site of contact 
(e.g., stomach/duodenum cells). 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a) which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union list of flavouring substances for use in or 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008b). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into 28 subgroups on the basis of structural similarity 
(EFSA, 2008b). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these α,β- unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 
212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded 
that a genotoxic potential could be ruled out and accordingly these substances will be evaluated using 
the Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
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To ease the data retrieval of the large number of structurally related alpha,beta-unsaturated substances 
in the different subgroups for which additional data are requested, EFSA has worked out a list of 
representative substances for each subgroup (EFSA, 2008bc). Likewise an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008bb).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.  
The Flavouring industry has now submitted additional data and the present FGE concerns the 
evaluation of some of these data requested on genotoxicity. 
TERMS OF REFERENCE 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on 4,5-epoxydec-2(trans)-enal [FL-no: 16.071], in accordance with Commission 
Regulation (EC) No 1565/2000. 
HISTORY OF EVALUATION 
The present Flavouring Group Evaluation 226 (FGE.226) concerns the evaluation of the genotoxic 
properties of one aliphatic aldehyde with the α,β-unsaturation in conjugation with an epoxide moiety. 
This substance was originally allocated to FGE.200 (FGE.19 subgroup 1.1.1). 
Subgroup 1.1.1 of FGE.19 originally covers 71 α,β-unsaturated aliphatic aldehydes. Seventy of these 
are simple, aliphatic, α,β-unsaturated aldehydes, or precursors for such, with or without additional 
double bonds, which is not in conjugation with the α,β-unsaturated structure. These 70 substances 
were allocated to subgroup 1.1.1(a) in FGE.200. The one remaining aliphatic, α,β-unsaturated 
aldehyde contains an epoxide moiety which is not present within the other 70 members of FGE.19 
subgroup 1.1.1. On this basis, it would be anticipated to have different chemical reactivity potential, 
and would have metabolic options that are not available to the other members of this subgroup. For 
these reasons, the Panel decided that this substance should be allocated to a separate subgroup, 
subgroup 1.1.1(b) and evaluated in a separate FGE, FGE.226.  
The present FGE.226 deals with the evaluation of the genotoxicity data submitted by the Flavour 
Industry for substance 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] from subgroup 1.1.1(b). 
ASSESSMENT 
1. PRESENTATION OF THE SUBSTANCE IN FGE.226 
1.1. Description 
The present Flavouring Group Evaluation 226 (FGE.226), corresponding to subgroup 1.1.1(b) of 
FGE.19, concerns one aliphatic aldehyde with the α,β-unsaturation in conjugation with a epoxide 
moity, 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]. The substance is shown in Table 1. 
The substance has previously been evaluated by the JECFA (JECFA, 2009c). A summary of the 
current evaluation status by the JECFA and the outcome of the present consideration is presented in 
Table 2. 
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1.2. Subgroup 1.1.1(b) 
As the α,β-unsaturated aldehyde and ketone structures are considered alerts for genotoxicity (EFSA, 
2008b) and the data on genotoxicity previously available did not rule out the concern for genotoxicity, 
the Panel has requested additional genotoxicity data for 4,5-epoxydec-2(trans)-enal according to the 
test strategy (EFSA, 2008bb). The chemical structure of the substance is shown in Table 1.1 
Table 1.1: Subgroup 1.1.1(b) of FGE.19 (EFSA, 2008bc) 
FL-no  
JECFA-no  
Subgroup  EU Register name  Structural formula  FEMA no  
CoE no  
CAS no  
16.071  
1570  
1.1.1  4,5-Epoxydec-2(trans)-enal  
O
O  
-  
-  
188590-62-7 
 
2. ADDITIONALLY SUBMITTED GENOTOXICITY DATA ON 4,5-EPOXYDEC-2(TRANS)-ENAL OF 
SUBGROUP 1.1.1(B)  
Introduction 
The Industry has submitted in vitro and in vivo genotoxicity data for the representative and only 
substance for this subgroup 1.1.1(b), 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] (EFFA, 2011n). 
2.1. In vitro Data 
In vitro genotoxicity assays have been performed in bacteria and mammalian cells with the α,β-
unsaturated aldehyde 4,5-epoxydec-2(trans)-enal [FL-no: 16.071]. 
2.1.1. Bacterial Reverse Mutation Assay 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 to assess the mutagenicity of 4,5-epoxydec-2(trans)-enal, both in the absence and in the 
presence of metabolic activation by (S9-mix), in two experiments (Sokolowski, 2001b). It is a GLP 
study conducted in accordance with OECD Guideline 471. An initial toxicity range-finding 
experiment was carried out in the absence and presence of S9-mix in strains TA98 and TA100 only, 
using final concentrations of 4,5-epoxydec-2(trans)-enal at 3, 10, 33, 100, 333 and 1000 μg/plate, plus 
negative (solvent) and positive controls. Evidence of toxicity, in terms of a decrease in revertant count, 
was apparent on all plates treated at 333 μg/plate and above in the absence and at 1000 μg/plate in the 
presence of S9-mix. The first experiment then evaluated all five strains in the absence and presence of 
S9-mix using plate incorporation methodology and final concentrations of either 1, 3, 10, 33, 100, and 
333 μg/plate (TA1535, TA1537 and TA102 without S9-mix) or 3, 10, 33, 100, 333 and 1000 μg/plate 
(TA1535, TA1537 and TA102 with S9-mix; TA100 and TA98 with and without S9-mix). Following 
these treatments, evidence of toxicity was observed in all strains at concentrations of 333 and/or 1000 
µg/plate, both in the absence and in the presence of S9-mix. No strains produced a biologically 
significant increase in the number of revertants.  
In the second experiment, treatments of all the tester strains were performed in the absence and 
presence of S9-mix using the same concentrations as in the first experiment. In order to increase the 
range of mutagenic detection, a second experiment was performed using the pre-incubation 
methodology in the absence and presence of S9-mix using the same concentrations as in the first 
experiment. Following these treatments, evidence of toxicity was again observed in all strains at 
Flavouring Group Evaluation 226
 
 
7 EFSA Journal 2012;10(7):2838 
concentrations of 333 and/or 1000 µg/plate. No biologically significant increases in the number of 
revertants were seen in any strain. 
It was concluded that 4,5-epoxydec-2(trans)-enal did not induce mutations in five strains of S. 
typhimurium when tested up to toxic concentrations in the absence and in the presence of a rat liver 
metabolic activation system (Sokolowski, 2001b). 
2.1.2. Micronucleus Assays 
4,5-Epoxydec-2(trans)-enal was assayed for the induction of chromosome damage, and potential 
aneugenic effects, in mammalian cells in vitro by examining the effect on the frequency of 
micronuclei in cultured human peripheral blood lymphocytes (whole blood cultures pooled from two 
healthy volunteers) treated in the absence and presence of rat liver metabolizing system (S9-mix) 
(Lloyd, 2009c). This GLP study complies with OECD Guideline 487. 4,5-Epoxydec-2(trans)-enal was 
added at 48 hours following culture initiation (stimulation by phytohaemagglutinin) either for 3 hours 
in the absence or presence of S9-mix, or for 24 hours in the absence of S9-mix. Cytochalasin B (6 
μg/ml) was added either at the start of treatment (24-hour treatments) or at the start of recovery (after 
3-hour treatments) in order to block cytokinesis and generate binucleate cells for analysis. It remained 
in the cultures until they were harvested 24 hours after the start of treatment. A preliminary range-
finding experiment had been conducted with and without S9-mix treatment in order to determine the 
effect of treatment upon Replication Index (RI), which was used as a basis for choosing a range of 
concentrations to be evaluated in the main study.  
In the main assay, micronuclei were analysed at multiple concentrations for each treatment group. For 
3-hour treatment without S9-mix the concentrations were 1.0, 2.0, 4.0 and 5.0 μg/ml, for 3-hour 
treatment with S9-mix the concentrations were 9.0, 10.5, and 12.0 μg/ml, and for 24-hour treatment 
without S9-mix the concentrations were 2.5, 3.0, 3.5 and 4.0 μg/ml. The levels of cytotoxicity 
(reduction in RI) at the top concentrations reached 61, 52 and 55 % in the 3-hour treatment in the 
absence of S9-mix, the 3-hour treatment in the presence of S9 and the 24-hour treatment in the 
absence of S9, respectively. These are within or very close to the target (50 - 60 %) range. One 
thousand binucleate cells per culture from two replicate cultures per concentration were scored for 
micronuclei. The study is therefore considered to comply with OECD Guideline 487. 
Following the 3-hour treatment without S9-mix, there was an increase in the frequency of 
micronucleated binucleate cells (MNBN) from 0.1 % in the solvent control to 0.65 % (p ≤ 0.01) and 
0.45 % (p ≤ 0.05) at the two highest concentrations. However, the increases observed at 4.000 and 
5.000 μg/mL were small and were exaggerated because the MNBN cell frequencies in both vehicle 
control cultures (0.1% in both cases) were at the lower end of the normal range (0 to 1.0 %). 
Furthermore, the MNBN cell frequencies in all treated cultures under this treatment condition fell 
within the 95th percentile of the normal range. Therefore these observations were not considered by the 
Authors to represent clear evidence of a biologically relevant response, although the results cannot be 
considered clearly negative.  
Following the 3-hour treatment in the presence of S9-mix at the highest concentration analysed (12.0 
μg/mL), the frequency of MNBN cells (2.25 %) was significantly higher (p ≤ 0.001) than those 
observed in concurrent vehicle controls (0.2 %). The MNBN cell frequencies in both cultures at 12.00 
μg/mL exceeded the normal ranges, and therefore this was considered to be a positive result. 
Similarly, for the 24-hour treatment at the lowest (2.5 μg/mL) and two highest concentrations (3.5 and 
4.0 μg/mL), the frequencies of MNBN cells were significantly higher (1.25 % p ≤ 0.05, 3.19 % p ≤ 
0.001 and 3.80 % p ≤ 0.001, respectively) than those observed in the concurrent vehicle control (0.65 
%). The MNBN cell frequencies in both cultures at each of these concentrations exceeded the normal 
ranges, and therefore this was again considered to be a positive result (Lloyd, 2009c). 
On the basis of these results, a new GLP study to determine whether 4,5-epoxydec-2(trans)-enal was 
acting as a clastogen or an aneugen using fluorescence in situ hybridization (FISH) analysis was 
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attempted (Lloyd, 2011e). Micronuclei were analysed at multiple concentrations for each treatment 
group, and the maximum concentrations were based on the toxicity displayed in the previous study. 
For 3-hour treatment with S9-mix the concentrations were 0, 12.0, 15.0 and 17.5 μg/ml, with MNBN 
cell frequencies of 0.30 %, 0.20 %, 0.50 % and 0.45 % respectively, with historical control range of 
0.0 - 0.7 %. For 24-hour treatment without S9-mix the concentrations were 0, 4.0, 5.0 and 7.5 μg/ml, 
with MNBN cell frequencies of 0.35 %, 0.25 %, 0.55 % and 0.20 % respectively, with a historical 
control range of 0.1 - 0.9 %. The levels of cytotoxicity (reduction in replication index, RI) were 16, 36 
and 48 % for the three concentrations in the three-hour treatment in the presence of S9-mix and 3, 10 
and 56 % for the three concentrations in the 24-hour treatment in the absence of S9-mix, respectively. 
48 and 56 % at the top concentrations are within or very close to the target (50 - 60 %) range. One 
thousand binucleate cells per culture from 2 replicate cultures per concentration were scored for 
micronuclei. The study is therefore considered to comply with OECD Guideline 487.  
The MNBN cell frequencies in all cultures under both treatment conditions fell within the normal 
range, thereby giving clear negative results. These data are in marked contrast to the previously 
described study (Lloyd, 2009c). Because no induction of micronuclei was observed following 3+21 
hours with S9-mix and 24+0 hours without S9-mix treatments, further analysis (FISH) was not 
conducted. Different blood donors were used in the first and second studies on 4,5-epoxydec-2(trans)-
enal. A subsequent study in which peripheral blood from the donors used in both experiments were 
compared in a single experiment confirmed the existence of a donor effect for this compound (data not 
provided). It is not known why this difference occurred, but the positive responses observed in the 
previous study (Lloyd, 2009c) cannot be dismissed. 
2.2. In vivo Data 
2.2.1. In vivo Micronucleus Assays 
On the basis of the in vitro micronucleus studies reported above, it was concluded that 4,5-epoxydec-
2(trans)-enal was an in vitro clastogen for human lymphocytes, although a donor effect, as described 
above, confounded the interpretation of the results. It was decided that it was most appropriate to carry 
out an in vivo micronucleus assay to determine whether the results obtained in the initial in vitro 
micronucleus assay could be confirmed in vivo. Therefore, groups of Han-Wistar rats were 
administered 4,5-epoxydec-2(trans)-enal via gavage and the induction of micronuclei in the 
polychromatic erythrocyte (PCE) of the bone marrow of treated rats was examined (Henderson D, 
2011). 
In an initial range-finding experiment to identify a maximum tolerated dose (MTD), groups of male 
and female (up to 3 animals/sex/group) Han-Wistar rats were administered 4,5-epoxydec-2(trans)-enal 
by oral gavage at doses of 250, 350, 500, 700, 1000, 1400, and 2000 mg/kg bw/day until an estimate 
of the MTD was established. Animals were dosed once daily for two consecutive days with the test 
article and observations made over a 2-day period following the final administration. Clinical signs of 
toxicity and body weight were recorded. At doses of 500 mg/kg bw/day and above, clinical signs of 
toxicity such as decreased activity and pilo-erection were observed in all animals, and mortality was 
induced. At doses of 350 mg/kg bw/day and below no clinical signs of toxicity were observed, except 
in one female at 350 mg/kg bw/day, for which decreased activity, pilo-erection and hunched posture 
were observed. Both male and female groups at 350 mg/kg bw/day showed mean body weight loss. 
On the basis of these concentrations, the MTD was considered to be 350 mg/kg bw/day. Additionally, 
as there were no substantive differences between sexes in apparent toxicity, only male animals were 
subsequently used in the micronucleus experiment. 
In the micronucleus experiment, groups of male (6 animals/group) rats were administered 4,5-
epoxydec-2(trans)-enal by oral gavage at 87.5, 175 and 350 mg/kg bw/day on 2 occasions 24 hours 
apart. Animals were sampled 24 hours after the final administration, thus enabling examination of 
cells exposed to the test article over a period of 24 to 48 hours prior to sampling. At the highest dose 
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on day 2, decreased activity was observed in all animals 1-hour post dose and at 2-hour post dose, 
pilo-erection was also noted in all animals. For the highest dose group one animal was found dead at 
end of day 2. These observations provide some indications that the animals were systemically exposed 
to the 4,5-epoxydec-2(trans)-enal. 
Rats treated with 4,5-epoxydec-2(trans)-enal at all doses exhibited group mean % PCE that were 
similar to the vehicle control group. These values were comparable with the historical control data for 
this experiment at the testing laboratory, thus confirming there was no evidence of test article related 
bone marrow toxicity. Additionally, rats treated with 4,5-epoxydec-2(trans)-enal at all doses exhibited 
MN PCE frequencies that were similar to the vehicle control group and which were considered 
consistent with the laboratory's historical data. There were no statistically significant increases in 
micronucleus frequency for any of the groups receiving the test article, compared to the concurrent 
vehicle control. On this basis, it was concluded that 4,5-epoxydec-2(trans)-enal did not induce 
micronuclei in the polychromatic erythrocytes of the bone marrow of male rats treated up to 350 
mg/kg/day (a dose which exceeded the maximum tolerated dose). 
2.3. Discussion of Mutagenicity/Genotoxicity Data 
4,5-Epoxydec-2(trans)-enal was unable to induce gene mutations in a valid Ames test. In a valid in 
vitro micronucleus assay, 4,5-epoxydec-2(trans)-enal was clearly positive in both treatments for 3+21 
hours in the presence of S9-mix and for 24+0 hours in the absence of S9-mix. In the same study, in the 
treatment for 3+21 hours in the absence of S9-mix, statistically significant increases of MNBN cell 
frequencies were reported at the two highest concentrations. These increases were not considered 
biologically relevant because the MNBN cell frequencies in the vehicle control cultures (0.1 %) were 
at the lower end of the historical control range (0.0 to 1.0 %) and because all the MNBN cell 
frequencies fell within the 95th percentile of the normal range. On this basis, the results of this study 
should be considered as equivocal. Overall, the results of this study indicate that 4,5-epoxydec-
2(trans)-enal is an in vitro genotoxic agent both in the presence and in the absence of metabolic 
activation. 
The positive results of the first study (Lloyd, 2009c) could not be confirmed in a second study, in 
which different blood donors were used (Lloyd, 2011e). According to the Authors, the existence of a 
donor effect for this substance was confirmed in a subsequent study in which peripheral blood from 
the donors used in both studies were compared in a single experiment. However, data related to this 
experiment were not provided and also an explanation for this difference was not given. Therefore, the 
concern for the genotoxic potential of 4,5-epoxydec-2(trans)-enal remains. 
4,5-Epoxydec-2(trans)-enal was found negative in a valid in vivo micronucleus assay in rats treated by 
oral gavage up to 350 mg/kg bw, considered as the MTD, on two occasions 24 hours apart. At this 
dose and below,  no clinical signs of toxicity were observed, except one female; both male and female 
groups showed only mean body weight loss. Clinical signs, including some mortality, were observed 
at the dose of 500 mg/kg bw, used in the initial range-finding experiment. At 350 mg/kg bw, there was 
no evidence of any test article-induced toxicity to the bone marrow. The Panel considered that 
lethality may indicate that the bone marrow was exposed, however this is not a proof. In addition, the 
negative results of this in vivo micronucleus assay do not allow to exclude site of contact effects. 
Therefore, an in vivo Comet assay should be performed.  
The request for a Comet assay is in line with the recommendations of the AFC Panel (EFSA, 2008bb) 
and Scientific Committee opinion on genotoxicity testing strategies applicable to food and feed safety 
assessment (EFSA, 2011ae). 
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3. CONCLUSION 
4,5-Epoxydec-2(trans)-enal did not induce gene mutations in bacterial cells (Ames test). It was 
positive in an in vitro micronucleus assay in cultured human lymphocytes with and without metabolic 
activation. Although these results could not be confirmed in a second study in which different blood 
donors were used, 4,5-epoxydec-2(trans)-enal is considered an in vitro genotoxic agent in the presence 
and in the absence of S9-mix. The negative results obtained in an in vivo micronucleus assay do not 
allow to exclude possible first site of contact effects. In addition, the Panel considered that lethality 
may indicate that the bone marrow were exposed, however this is not a proof. On this basis, an in vivo 
Comet assay in rodents is required, in order to verify possible genotoxic effects at the first site of 
contact (e.g., stomach/duodenum cells). 
The request for a Comet assay is in line with the recommendations of the AFC Panel (EFSA, 2008bb) 
and Scientific Committee opinion on genotoxicity testing strategies applicable to food and feed safety 
assessment (EFSA, 2011ae). 
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SPECIFICATION SUMMARY OF THE SUBSTANCE IN THE FGE.200REV2 (JECFA, 2009B)  
Table 1:  Table 1: Specification Summary of the Substances in the Present Group (JECFA, 2009b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
16.071 
1570 
4,5-Epoxydec-2(trans)-enal  
O
O
 
- 
- 
188590-62-7 
 
 
Liquid 
C10H16O2 
168.23 
Soluble 
Soluble 
80-83 (0.8 hPa) 
 
IR NMR MS 
87 % 
1.472-1.478 
0.943-0.949 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
 
CURRENT SAFETY EVALUATION STATUS APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) (JECFA, 
2002C) 
Table 2:  Table 2: Summary of Safety Evaluation of the JECFA Substance in the Present Group (JECFA, 2009c) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
( genotoxicity) 
 
16.071 
1570 
4,5-Epoxydec-2(trans)-enal 
O
O
0.061 
0.2 
Class III 
A3: Intake below threshold 
4) Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated in FGE.226, an in vivo Comet 
assay is requested.  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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GENOTOXICITY (IN VITRO)  
Table 3:  Summary of Additionally Submitted In Vitro Genotoxicity Data on 4,5-Epoxydec-2(trans)-enal 
FL-no Chemical Name Test System in vitro Test Object  Concentrations of Substance 
and Test Conditions  
Result  Reference  Comments  
[16.071] 4,5-Epoxydec-2(-trans)-enal Reverse Mutation S. typhimurium TA98, TA100 3-1000 μg/plate [1,2] 
3-1000 μg/plate [1,3]  
Negative (Sokolowski, 
2001b) 
Valid GLP study in compliance with 
OECD Guideline 471 
S. typhimurium TA1535, 
TA1537 and TA102 
1-333 μg/plate [2,4] 
3-1000 μg/plate [2,5] 
1-333 μg/plate [3,4] 
3-1000 μg/plate [3,5] 
Negative Valid GLP study in compliance with 
OECD Guideline 471 
Micronucleus 
induction 
Human peripheral blood 
lymphocytes 
1.0-5.0 μg/ml [4,6] Equivocal (Lloyd, 
2009c) 
Valid GLP study in compliance with 
OECD Guideline 487. Increases at 4.0 
and 5.0 micrograms/ml are of doubtful 
biological relevance due to low vehicle 
control and because are within the 95th 
percentile of the normal range. 
9.0-12.0 μg/ml [5,6],  
2.5-4.0 μg/ml [4,7] 
Positive Complies with draft OECD guideline 
487. Acceptable levels of cytotoxicity 
achieved at the top concentrations used 
in all parts of the study. 
12.0-17.5 μg/ml [5,6]; 
4.0-7.5 μg/ml [4,7] 
Negative (Lloyd, 
2011e) 
Complies with draft OECD guideline 
487. Acceptable levels of cytotoxicity 
achieved at the top concentrations used 
in all parts of the study. 
*  Values were converted from reported μM or nM concentrations to μg values. 
[1] With and without S9 metabolic activation. 
[2] Plate incorporation method. 
[3] Pre-incubation method. 
[4] Without S9 metabolic activation. 
[5] With S9 metabolic activation. 
[6] 3-hours incubation with 21-hours recovery period. 
[7] 24-hours incubation with no recovery period. 
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GENOTOXICITY (IN VIVO)  
 
Table 4:  Table 4: Summary of Additionally Submitted In Vivo Genotoxicity Data on 4,5-Epoxydec-2(trans)-enal 
FL-no Chemical Name Test System in vivo Test Object 
Sex/No per 
group 
Route  Concentrations of Substance 
and Test Conditions  
Result Reference  Comments  
[16.071] 4,5-Epoxydec-2(-trans)-enal Micronucleus assay Han-Wistar rats  
Male / 6 
Gavage 87.5, 175, and 350 mg/kg 
bw/day 
Negative (Henderson, 
2011) 
Complies with draft OECD guideline 
474. No evidence of test article 
related bone marrow toxicity at the 
top dose. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
CPA  Cyclophosphamide 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MMC  Mitomycin 
MNBN  Micronucleated Binucleated 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
MTD  Maximum tolerated dose 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocyte 
PHA  Phytohaemagglutinin 
(Q)SAR (Quantitative) Structure-Activity Relationship 
RI  Replication Index 
SCF  Scientific Committee on Food 
VIN  Vinblastine 
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WHO  World Health Organisation 
